1-3 of 3
Michael Schwarzinger, MD
Close
Sort by
Journal Articles

Cost-Effectiveness of Antifungal Strategies in High-Risk Neutropenic Patients.

Michael Schwarzinger, MD, PhD, Sylvain Baillot, MSc, Céline Beauchamp, MSc, Sébastien Maury, MD, PhD, Cécile Pautas, MD, Anne Vekhoff, MD, Hassan Farhat, MD, Felipe Suarez, MD, Mathieu Kuentz, MD, Catherine Cordonnier, MD
Journal: Blood
Blood (2007) 110 (11): 4340.
https://doi.org/10.1182/blood.V110.11.4340.4340
Published: 2007
Journal Articles

Empirical Versus Pre-Emptive Antifungal Therapy in High-Risk Febrile Neutropenic Patients: A Prospective Randomized Study.

Catherine Cordonnier, MD, Cecile Pautas, MD, Sebastien Maury, MD, PhD, Anne Vekhoff, MD, Hassan Farhat, MD, Felipe Suarez, MD, Maria Basile, MD, Francoise Isnard, MD, Lionel Ades, MD, Frederique Kuhnoski, MD, Oumady Reman, MD, Sami Chehata, MD, Thierry De Revel, MD, Stephane Lepretre, MD, Emmanuel Raffoux, MD, Stephane Bretagne, MD, PhD, Michael Schwarzinger, MD
Journal: Blood
Blood (2006) 108 (11): 2019.
https://doi.org/10.1182/blood.V108.11.2019.2019
Published: 2006
Journal Articles

Empirical Versus Pre-Emptive Antifungal Therapy in High-Risk Febrile Neutropenic Patients: An Economic Analysis.

Michael Schwarzinger, MD, PhD, Celine Beauchamp, PhD, Sebastien Maury, MD PhD, Cecile Pautas, MD, Anne Vekhoff, MD, Hassan Farhat, MD, Felipe Suarez, MD, François Hemery, MD, Mathieu Kuentz, MD, Patrick Maison, MD PhD, Catherine Cordonnier, MD
Journal: Blood
Blood (2006) 108 (11): 2021.
https://doi.org/10.1182/blood.V108.11.2021.2021
Published: 2006